Recombinant adenoviral Vectors and their usefulness in the treatment of various types of liver fibrosis, renal, pulmonary and hipertru00d3ficas scars

摘要

We propose the use of gene therapy for its application in the treatment of various fibrosis in humans.The goal is the use of "Therapeutic genes specifically to target organs to reverse and / or prevent the development of the process associated with fibrosis.The potential Application of gene therapy to patients with cirrhosis and / or fibrosis will depend in large part on the successful sending of genes coding for proteins in livers with Fibrosis and therapeuticXtensa and that these genes encode Proteins that mmp-8 Latent and active mmp-1, mmp-2,Mmp-9, UPA and MMP - 13; wild and / or modified (or its truncated Version); truncated Receptor Type II TGF beta and are led by Smad7 adenovirus recombinant Vectors and / or other non transduzcan (Infection of other organs of the economy). The recombinant adenovirus (ADR) are highly efficient vectors for transduction of Therapeutic genes to target cells.We have proven that we can deliver genes to cirrhotic livers.The delivery of Therapeutic genes by these adenoviral Vectors and recombinant vectors may be made using cationic and Anionic Liposomes (DOTMA).We also propose the use of this Patent to equally be applied to: * * pulmonary fibrosis, renal fibrosis,* hypertrophic and Keloid scarring (fibrosis) of the skin and other types of fibrosis.